journal article·2025-02Open access

Multifunctional Thermoelectric Nanocatalysts for Synergistic Uveal Melanoma Treatment by Specific Cuproptosis and Pyroptosis

Muyue Yang, Xiaoyan Jiang, Mingyang Song, Wei Feng, Yu Chen, Ping Gu, Xianqun Fan

Advanced Functional Materials· Volume 35· Issue 8

Abstract

Abstract Uveal melanoma (UM) is a highly aggressive ocular malignancy associated with a poor prognosis and significant resistance to conventional therapies, including surgical resection, chemotherapy, and radiotherapy, which are often limited by their efficacy and adverse side effects. Energy‐conversion‐based nanodynamic therapy, which facilitates the generation of reactive oxygen species (ROS), has emerged as a promising approach for cancer treatment. Here, the development of high‐performance multifunctional thermoelectric nanocatalysts, specifically Cu5FeS3.6Se0.4 nanoparticles, optimized for the effective synergistic treatment of UM is reported. These nanoparticles exhibit remarkable photothermal, thermoelectric, and chemodynamic properties that enhance therapeutic efficacy. Under near‐infrared light irradiation, Cu5FeS3.6Se0.4 nanoparticles generate localized hyperthermia, which not only induces direct tumor cell ablation but also produces thermoelectric potentials that facilitate ROS generation. Additionally, the hyperthermia induced by the photothermal effects of these nanoparticles accelerates a Fenton‐like reaction, leading to the formation of highly reactive hydroxyl radicals for chemodynamic therapy. The resultant ROS induce oxidative stress within tumor cells, promoting mechanisms such as cuproptosis and pyroptosis. The integration of photothermal effects, thermoelectric potentials, and chemodynamic therapy within a single nanoplatform represents an efficient strategy for UM treatment, addressing the shortcomings of traditional therapies and offering a highly effective means of managing this aggressive cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Ocular Oncology and Treatments · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Ophthalmology Shanghai Ninth People's Hospital Shanghai Jiaotong University School of Medicine Shanghai 200011 China

Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology Shanghai 200011 China

School of Medicine Shanghai University Shanghai 200444 P. R. China

Materdicine Lab School of Life Sciences Shanghai University Shanghai 200444 P. R. China

Funding

National Natural Science Foundation of China · China Postdoctoral Science Foundation

References (40)

Show source-provided references
1. 10.1056/NEJMoa210348510.1056/NEJMoa2103485 ↗
2. 10.1002/cncr.2972710.1002/cncr.29727 ↗
3. 10.1038/s41572-020-0158-010.1038/s41572-020-0158-0 ↗
4. 10.1200/JCO.20.0055010.1200/JCO.20.00550 ↗
5. 10.2217/fon-2021-126010.2217/fon-2021-1260 ↗
6. 10.1038/s41571-022-00714-110.1038/s41571-022-00714-1 ↗
7. 10.1038/s41591-022-02015-710.1038/s41591-022-02015-7 ↗
8. 10.1016/S1470-2045(17)30251-610.1016/S1470-2045(17)30251-6 ↗
9. 10.1038/eye.2016.27510.1038/eye.2016.275 ↗
10. 10.1016/j.preteyeres.2019.10080010.1016/j.preteyeres.2019.100800 ↗
11. 10.1016/j.addr.2020.06.00610.1016/j.addr.2020.06.006 ↗
12. 10.1002/anie.20220048010.1002/anie.202200480 ↗
13. 10.1021/jacs.0c1233010.1021/jacs.0c12330 ↗
14. 10.1002/anie.20151003110.1002/anie.201510031 ↗
15. 10.1002/anie.20171202710.1002/anie.201712027 ↗
16. 10.1038/s41573-024-00979-410.1038/s41573-024-00979-4 ↗
17. 10.1039/D0CS00664E10.1039/D0CS00664E ↗
18. 10.1002/adma.20200506210.1002/adma.202005062 ↗
19. 10.1038/d41573-023-00094-w10.1038/d41573-023-00094-w ↗
20. 10.1002/adma.20210422310.1002/adma.202104223 ↗
21. 10.1039/D3CS00162H10.1039/D3CS00162H ↗
22. 10.1038/s41568-020-0265-y10.1038/s41568-020-0265-y ↗
23. 10.1038/s41568-021-00435-010.1038/s41568-021-00435-0 ↗
24. 10.1002/adma.20210677310.1002/adma.202106773 ↗
25. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
26. 10.1002/adma.20240856010.1002/adma.202408560 ↗
27. 10.1002/anie.20180566410.1002/anie.201805664 ↗
28. 10.1038/nrc.2018.410.1038/nrc.2018.4 ↗
29. 10.1038/s41467-023-40470-z10.1038/s41467-023-40470-z ↗
30. 10.1002/smll.20210386810.1002/smll.202103868 ↗
31. 10.1002/anie.20231815510.1002/anie.202318155 ↗
32. 10.1002/anie.20230702010.1002/anie.202307020 ↗
33. 10.1002/adma.20180827810.1002/adma.201808278 ↗
34. 10.1002/adma.20230674810.1002/adma.202306748 ↗
35. 10.1002/adma.20230798010.1002/adma.202307980 ↗
36. 10.1002/smll.20210459210.1002/smll.202104592 ↗
37. 10.1002/adma.20220881710.1002/adma.202208817 ↗
38. 10.1016/j.lfs.2019.11714810.1016/j.lfs.2019.117148 ↗
39. 10.1155/2016/672458510.1155/2016/6724585 ↗
40. 10.1002/adma.20221226710.1002/adma.202212267 ↗